FDA Warns Lymol Medical for Failing Postmarketing Step

Drug Industry Daily
A A
The FDA issued a warning to Lymol Medical for failing to submit a final postmarketing requirement (PMR) report on its sterile talc product without providing a good explanation for the delay.

To View This Article:

Login

Subscribe To Drug Industry Daily